Q2 2026 saw 4.5% sales growth to SEK 200 million and a 27% EBITDA margin, with record Americas sales and strong reagent growth in APAC offsetting EMEA inventory adjustments and China headwinds. Bone marrow application launch and FPM technology progress support a positive outlook.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.